Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 5/20 | 0.41 |
| ▸ | ARG2 | P78540 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102119 | 1.00 | GRM2 (0.50) | GRM2GRM3ARG1ARG2CYP2D6 | |
| SCHEMBL24520182 | 0.83 | GRM2 (0.49) | GRM2GRM3ARG1ARG2CYP2D6 | |
| SCHEMBL7514187 | 0.79 | GRM2 (0.39) | GRM2GRM3CYP2D6ALOX5HPGD | |
| SCHEMBL12504986 | 0.76 | GRM2 (0.45) | GRM2GRM3CYP2D6ALOX5HPGD | |
| SCHEMBL6282895 | 0.76 | GRM2 (0.53) | GRM2GRM3CYP2D6ALOX5HPGD | |
| SCHEMBL21389631 | 0.75 | GRM2 (0.36) | GRM2GRM3ARG1ARG2 | |
| SCHEMBL8957923 | 0.74 | GRM2 (0.51) | GRM2GRM3ARG1ARG2CYP2D6 | |
| SCHEMBL3614328 | 0.74 | GRM2 (0.51) | GRM2GRM3ARG1ARG2CYP2D6 | |
| SCHEMBL3614325 | 0.74 | GRM2 (0.51) | GRM2GRM3ARG1ARG2CYP2D6 | |
| SCHEMBL8266853 | 0.73 | GRM2 (0.42) | GRM2GRM3CYP2D6ALOX5HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239335-B1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | AJINOMOTO KK (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8372607-B2 | Method for producing serine derivative and protein used for the same | AJINOMOTO CO., INC. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | AJINOMOTO CO., INC. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2239335-A1 | PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS | Ajinomoto Co., Inc. (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317068-A1 | METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME | SPR, AMD1, DAO | GRM2 4187/4885GRM3 4589/4885ARG1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.